SEP 27 2026
Elevar Therapeutics — lirafugratinib
for cholangiocarcinoma
Accepted MAR 30 2026.
About
Cholangiocarcinoma is a bile duct cancer that causes abdominal pain, jaundice, and severe itching as tumors block bile flow. Lirafugratinib blocks FGFR2, a protein that drives tumor growth when its genetic code gets scrambled into abnormal fusion patterns. By targeting these faulty FGFR2 signals, the drug may slow cancer progression in patients whose tumors rely on this specific molecular malfunction.
Pivotal trial
The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement. Participants will: * Take lirafugratinib regularly as instructed by their study doctor
Source: ClinicalTrials.gov
Drug Watch — recent news on lirafugratinib
- Dr Goyal on the Safety Profile of Lirafugratinib in FGFR2-Altered Cholangiocarcinoma - OncLive
- Dr Goyal on Efficacy Data With Lirafugratinib in FGFR2-Altered Cholangiocarcinoma - OncLive
- Dr Goyal on the Unique Mechanism and Selectivity of Lirafugratinib in FGFR2-Altered CCA - OncLive
- FDA Grants Priority Review to Lirafugratinib in FGFR2+ Cholangiocarcinoma - CancerNetwork
- FDA Grants Lirafugratinib Priority Review in FGFR2-Altered Cholangiocarcinoma - Targeted Oncology